Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000 Shares Of Newly Created Series C Convertible Preferred Stock With An Aggregate Stated Value Of $12M
BBenzingaBenzinga Newsdesk
Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company") today announced that it has closed its acquisition of an 11% fully diluted equity interest in SOD Sciences, Inc. ("SOD Sciences"
Vivos Therapeutics announced its financial results for the third quarter of 2026, reporting a 24% quarter-over-quarter revenue increase to $6.4 million and an 18% year-over-year improvement in operating loss.
Vivos Therapeutics reported Q3 2026 revenue of $6.4 million, up 24% quarter-over-quarter, with operating loss improving 18% year-over-year to $3.9 million. The company reduced annual operating costs by $5 million, exchanged $6.1 million of debt for equity, and regained Nasdaq compliance with stockholders' equity requirements following the October 2026 SOD Sciences acquisition. Management expects new clinical initiatives and payer contract renegotiations to contribute to revenue growth beginning Q4 2026.
Vivos Therapeutics reported a Q3 loss of $0.07 per share, beating consensus estimates of $0.30 loss by 76.67%. Revenue came in at $6.41 million, surpassing estimates by 17.15%, though down from $6.78 million year-ago. The stock has declined 95.2% year-to-date and carries a Zacks Rank #3 (Hold) rating with mixed estimate revisions.